Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 14/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815744 | 0.87 | S1PR4 (0.39) | NPC1RAB9ASMN1; SMN2S1PR4LMNA | |
| SCHEMBL17815734 | 0.83 | S1PR4 (0.55) | NPC1RAB9ASMN1; SMN2S1PR4LMNA | |
| SCHEMBL20820251 | 0.82 | HDAC1 (0.33) | S1PR4KDM4E | |
| SCHEMBL17811774 | 0.81 | — | — | |
| SCHEMBL17815784 | 0.80 | S1PR4 (0.46) | NPC1S1PR4LMNAHPGDMAPT | |
| SCHEMBL27849575 | 0.79 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2S1PR4LMNA | |
| SCHEMBL17815727 | 0.78 | APOBEC3A (0.35) | NPC1RAB9ASMN1; SMN2S1PR4LMNA | |
| SCHEMBL26414389 | 0.76 | RECQL (0.33) | LMNAALDH1A1 | |
| SCHEMBL20116553 | 0.75 | KDM4E (0.51) | NPC1RAB9ASMN1; SMN2LMNAHPGD | |
| SCHEMBL17815785 | 0.75 | MAPK1 (0.41) | NPC1RAB9ASMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | NPC1 1085/4885RAB9A 1177/4885SMN1; SMN2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.